Skip to main content
. Author manuscript; available in PMC: 2023 Mar 2.
Published in final edited form as: Cancer Discov. 2023 Mar 1;13(3):598–615. doi: 10.1158/2159-8290.CD-22-0968

Figure 6. Clinical activity of NVL-520.

Figure 6.

(A) Representative computed tomography (CT) images demonstrating a confirmed partial response (PR) to NVL-520 in a patient with CD74-ROS1 fusion-positive lung adenocarcinoma with a ROS1 G2032R resistance mutation after prior crizotinib, lorlatinib, and chemotherapy. Patient started at 25 mg QD NVL-520 and then increased to 75 mg QD at 8 weeks. Blue arrows indicate left lung nodules that decreased in size over the course of treatment. (B) Representative CT (upper panel) and magnetic resonance imaging (lower panel) images demonstrating a confirmed PR to NVL-520 in a patient with EZR-ROS1 fusion-positive lung adenocarcinoma with a ROS1 G2032R resistance mutation after prior entrectinib, repotrectinib, and chemotherapy. Patient started at 50 mg NVL-520 and then escalated to 75 mg at 12 weeks. Blue arrows in the upper panel indicate segment 5/6 and 3 liver metastases with continuous regression over the course of treatment. Blue arrow in the lower panel indicates a right occipital lobe metastasis that decreased in size at week 4 and became barely appreciable at week 16.